2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Fiche du document
2014
- doi: 10.1093/annonc/mdu123
- issn: 0923-7534
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdu123
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/24669016
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1569-8041
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EF7F13CAC7577
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
illnessCiter ce document
B. Besse et al., « 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. », Serveur académique Lausannois, ID : 10.1093/annonc/mdu123
Métriques
Partage / Export
Résumé
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.